The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...

Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Lilly's retatrutide shows remarkable weight loss in trials but raises concerns with side effects possibly linked to the drug like nausea and kidney stones. Read more here.

Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.